Current therapeutic interventions for aneurysmal subarachnoid hemorrhage remain limited, with cerebral vasospasm and ischemia continuing to cause significant morbidity and mortality despite successful aneurysm occlusion.
No takes yet. Share an insight, caveat, or question.
Vasospasm drives ongoing morbidity after aneurysm occlusion; leaves open the search for effective pharmacological prevention in subarachnoid hemorrhage.
Grasso et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: